Ravulizumab – March 2023

• Brand names:
  • Ultomiris®
• Pharmaceutical Company:
  • Alexion Pharmaceuticals Australasia Pty Ltd
• Condition/Indication: Atypical haemolytic uraemic syndrome
• Meeting Date: March 2023
• Public Summary Document (PSD) March 2023 July 2023 PBAC Meeting - (PDF 887KB)
• Public Summary Document (PSD) March 2023 July 2023 PBAC Meeting - (Word 224KB)

Related public summary document

• Ravulizumab – July 2020
• Ravulizumab – July 2021
• Ravulizumab – July 2023